Celltrion Healthcare, under the leadership of Hyung-Ki Kim, made a significant announcement on October 18th. The company has successfully maintained its leading market position by securing contracts for 'Remsima (containing Infliximab)' in recent Infliximab tenders in major European countries.

In a remarkable achievement, Remsima emerged as the winner in a tender organized by Agence Générale des Equipements et Produits de Santé (AGEPS) in France, one of the major five European countries (EU5). Consequently, Celltrion Healthcare is now the chosen supplier for Remsima to the university hospital consortium of Paris and Île-de-France region, Assistance Publique - Hôpitaux de Paris (APHP), beginning this month and continuing until 2026.

As per data from IQVIA, a prominent pharmaceutical market research organization, Remsima has secured a remarkable 59% market share in France in the second quarter of this year, outperforming both the originator and competing products. The recent success in the AGEPS tender is expected to further reinforce Remsima's influence in France.

Remsima has also achieved success in another EU5 country, Italy. Celltrion Healthcare secured the contract for Remsima in an Infliximab tender held in Umbria, a region in central Italy.

In the third quarter, Celltrion Healthcare demonstrated its direct sales competitiveness by securing contracts for Yuflyma (containing Adalimumab) in tenders organized by five Italian regional governments. Leveraging the capabilities of its local subsidiary, the company is steadily expanding the market share of its entire autoimmune disease product portfolio, including Remsima and Yuflyma.

Celltrion Healthcare attributes its continued success in tenders to the "product competitiveness" of Remsima, which has been a stalwart in the European market for a decade. With a proven track record of effectiveness and safety in the medical field for over 20 years, Remsima's introduction as Remsima SC, the world's only subcutaneous Infliximab product, has significantly increased its preference among European medical professionals and patients.

Celltrion Healthcare's dual formulation strategy, where patients switch to Remsima and then continue with Remsima SC for maintenance therapy, has bolstered its market share. The company foresees further expansion, particularly with the growing prescription of Remsima SC across Europe.

In addition, the pending merger with Celltrion promises to bring improved cost efficiencies, enabling the company to lead in competitive bidding and expand the market presence of Remsima. The improved cost structure resulting from the merger will not only boost the merged company's revenue but also allow for the establishment of a more differentiated pricing strategy. This, in turn, will facilitate active participation in more bidding competitions throughout Europe, ultimately expanding Remsima's market share.

A representative from Celltrion Healthcare emphasized that Remsima's enduring success in Europe is due to the unwavering trust of local medical professionals and patients in its exceptional product competitiveness. They affirmed the company's commitment to maintaining Remsima's position as a leading treatment for autoimmune diseases, with a strong focus on the synergy between Remsima and Remsima SC and the cost-efficiency benefits of the impending merger.